One email when the decision is public, with what it means in plain language. You'll also get new trials and FDA news for Limb-Girdle Muscular Dystrophy. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
The FDA is expected to decide on BBP-418 for Limb-girdle muscular dystrophy type 2I/R9 by November 27, 2026, under an NDA from BridgeBio Pharma.
What the FDA is deciding on BBP-418 for Limb-Girdle Muscular Dystrophy
The FDA is reviewing BridgeBio Pharma's application to approve BBP-418 for limb-girdle muscular dystrophy type 2I/R9. Oral ribitol therapy under priority review; LGMD2I/R9 has no approved treatment.
Who the BBP-418 decision matters to
Limb-Girdle Muscular Dystrophy (LGMD) refers to a genetically heterogeneous group of muscular dystrophies characterized by progressive weakness of the hip and shoulder girdle muscles. Multiple genetic subtypes are recognized, with both autosomal dominant and autosomal recessive inheritance patterns.
LGMD encompasses more than 30 genetic forms, each caused by mutations in different genes encoding proteins essential for muscle structure and function.
Prevalence: Approximately 1 per 14,500 to 1 per 123,000 people depending on geographic region; exact prevalence varies by subtype. See our full Limb-Girdle Muscular Dystrophy page for current treatments, recruiting trials, and community resources.
How BBP-418 works
BBP-418: oral glycosylation substrate: ribitol, which the body turns into CDP-ribitol, the building block the FKRP enzyme uses to finish the sugar coat on alpha-dystroglycan. Our full BBP-418 profile covers how it works, side effects in plain language, and its trial history.
What an approval or a rejection of BBP-418 would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. The letter describes what the FDA wants addressed, and the company then decides whether to resubmit, run more studies or stop. Either way, this page updates with the outcome and what it means.
Where Limb-Girdle Muscular Dystrophy treatment stands today
Read our full Limb-Girdle Muscular Dystrophy treatment summary
Research in Limb-Girdle Muscular Dystrophy is increasingly tailored to individual genetic subtypes, recognizing that different mutations require different therapeutic approaches. Gene therapy approaches designed for specific mutations, exon-skipping therapies, and gene editing technologies are all being tested for appropriate subtypes.
Trials carefully measure muscle strength through functional testing and imaging while monitoring biomarkers that predict response. Because LGMD encompasses many genetic types, trials often enroll patients with different mutations in separate cohorts or analyze them as distinct subgroups.
Emerging treatment strategies include pharmacological chaperones that restore protein function, antisense oligonucleotides, and protein replacement approaches tailored to your specific genetic defect. Knowing your precise LGMD subtype through genetic testing is essential for identifying which trials target your specific mutation.
The Limb-Girdle Muscular Dystrophy page has every treatment and trial →Meanwhile, 6 Limb-Girdle Muscular Dystrophy studies are open or about to open
Whatever the FDA decides here, research on Limb-Girdle Muscular Dystrophy does not stop. Of these, 2 test a treatment; the others follow patients over time. The most recently updated:
We'll email you when the decision is public, with what it means in plain language, and when new trials open for Limb-Girdle Muscular Dystrophy. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Frequently asked questions
When will the FDA decide on BBP-418?
The FDA's target date (PDUFA date) for BBP-418 in Limb-girdle muscular dystrophy type 2I/R9 is November 27, 2026.
Who disclosed it: BridgeBio Pharma. The FDA does not publish these dates.
Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.
Source: BridgeBio announcement
What is BBP-418 being reviewed for?
BridgeBio Pharma submitted an NDA for BBP-418 in Limb-girdle muscular dystrophy type 2I/R9.
What to know: Oral ribitol therapy under priority review; LGMD2I/R9 has no approved treatment.
How it works: Oral glycosylation substrate: ribitol, which the body turns into CDP-ribitol, the building block the FKRP enzyme uses to finish the sugar coat on alpha-dystroglycan.
More: the BBP-418 drug page explains it in plain language.
Is there already an FDA-approved treatment for Limb-Girdle Muscular Dystrophy?
No. No medicine's current FDA label names Limb-Girdle Muscular Dystrophy, checked October 21, 2026.
Check: the Limb-Girdle Muscular Dystrophy page also searches FDA drug labels for approved treatments.
What did the BBP-418 trials show?
FORTIFY (NCT05775848) is a 3-year Phase 3 trial of 112 people aged 12 to 60 with LGMD2I/R9, randomized 2 to 1 to BBP-418 or placebo at 21 sites, 13 in the US. At its 12-month interim analysis, glycosylated alpha-dystroglycan rose about 1.8 times by month 3, creatine kinase fell 82%, walking speed on a 100-meter timed test rose 0.14 m/s against a 0.12 m/s decline on placebo, and lung function (FVC) rose about 3 points of predicted, about 5 points better than placebo. In an exploratory heart analysis, every evaluable person on BBP-418 whose high-sensitivity troponin I was raised at the start was back in the normal range at month 12, against 40% on placebo.
More: the BBP-418 drug page has the full trial history and sources.
What are the side effects of BBP-418?
In the Phase 3 FORTIFY trial's 12-month analysis, side effects were about as common as on placebo. The most common on BBP-418 were diarrhea (39.2% vs 52.6% on placebo, all mild to moderate), pain after a study procedure (20.3% vs 10.5%), falls (18.9% vs 26.3%), common cold symptoms (17.6% vs 21.1%), nausea (16.2% vs 7.9%) and joint pain (14.9% vs 10.5%).
More: the BBP-418 drug page has the safety details reported so far.
Can I get BBP-418 before the FDA decides?
Usually only through a clinical trial or an expanded access program, and the company decides whether to offer one.
Trials: 6 Limb-Girdle Muscular Dystrophy studies are open or about to open, 2 of them testing a treatment. See them.
Check your fit: Match Me compares your details with every open trial.
Expanded access: your doctor can ask BridgeBio Pharma directly. Registered programs are listed on ClinicalTrials.gov.
How much will BBP-418 cost?
BridgeBio Pharma has not announced a price. Drugmakers usually set it around approval.
Help paying: drugmaker programs and charity funds usually open at launch.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the BBP-418 decision?
This page updates with the outcome the day it is announced.
If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from BridgeBio announcement. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.